User Guide for Howe Sound Research models including: 325, CANPANEL 325 Weather Aging Testing Melaka, CANPANEL 325, Weather Aging Testing Melaka, Testing Melaka, Melaka
Cancer Gene Panels and Profiling Markets | Howe Sound Research - Howe Sound Research SEE the
File Info : application/pdf, 24 Pages, 362.39KB
DocumentDocumentRESEARCH REPORT GENOMIC CANCER PANEL AND PROFILING MARKETS BY CANCER, BY APPLICATION, BY TISSUE AND BY GENE TYPE WITH SCREENING POTENTIAL MARKET SIZE. WITH EXECUTIVE AND CONSULTANT GUIDES. INCLUDES IMPACT OF AI. 2025-2029 Cancer Panel and Profiling Markets Page | 2 Howe Sound Research is a market research and consulting company based in Vancouver, British Columbia, Canada. In our spare time we like to sail in a large body of water nearby called Howe Sound. We publish market research reports that address scientific industries with an emphasis on Biotechnology and Clinical Diagnostic markets. We consider ourselves experts in these areas. We approach market research differently than other companies. At any one time we have a limited number of reports, and we update them frequently, sometimes several times a year. Our reports are prepared by people who understand the industry and have worked and studied in the area. This contrasts with the many research mills who produce canned reports on the Handbag market one day and the XRay market the next. Our intellectual property is encryption protected. If you have issues with this or would like to upgrade to a corporate license that is not encrypted, please contact us at the email above. Please feel free to contact us if you have any questions. We believe in customer service and are more than willing to provide after sales assistance and custom data. HOWE SOUND RESEARCH Cancer Panel and Profiling Markets Page | 3 All Rights Reserved. This document contains copyrighted intellectual property. No part of it may be circulated, copied, quoted, or otherwise reproduced without the approval of Howe Sound Research. Please respect our intellectual property and do not distribute this document beyond the terms of your license. HOWE SOUND RESEARCH Cancer Panel and Profiling Markets Page | 4 Table of Contents 1 Market Guides ..................................................................................................................25 1.1 Cancer Panel Market - Strategic Situation Analysis ...................................................... 26 1.2 Large Comprehensive Cancer Panel Market - Situation Analysis................................ 28 1.3 Guide for Executives, Marketing, Sales and Business Development Staff ................... 31 1.4 Guide for Management Consultants and Investment Advisors ................................... 33 1.5 Impact of Artificial Intelligence on Cancer Profiling Market ........................................ 34 2 Introduction and Market Definition ................................................................................35 2.1 What are Cancer Gene Panels and Profiling? .............................................................. 36 2.2 The Sequencing Revolution............................................................................................. 39 2.3 Market Definition .............................................................................................................. 41 2.3.1 Revenue Market Size.................................................................................................... 41 2.4 Methodology.................................................................................................................... 43 2.4.1 Methodology ................................................................................................................ 43 2.4.2 Sources .......................................................................................................................... 43 2.4.3 Authors .......................................................................................................................... 43 2.5 Perspective: Healthcare Spending................................................................................. 45 2.5.1 Global Healthcare Spending ...................................................................................... 45 2.5.2 Spending on Healthcare and Pharmaceuticals........................................................ 47 2.5.3 Spending on Diagnostics ............................................................................................. 47 HOWE SOUND RESEARCH Cancer Panel and Profiling Markets Page | 5 2.5.4 Important Role of Insurance for Medical Services..................................................... 47 3 Market Overview..............................................................................................................49 3.1 Players in a Dynamic Market........................................................................................... 50 3.1.1 Academic Research Lab ............................................................................................ 52 3.1.2 Diagnostic Test Developer........................................................................................... 52 3.1.3 Instrumentation Supplier .............................................................................................. 53 3.1.4 Chemical/Reagent Supplier........................................................................................ 53 3.1.5 Pathology Supplier ....................................................................................................... 53 3.1.6 Independent Clinical Laboratory ............................................................................... 54 3.1.7 Public National/regional Laboratory .......................................................................... 54 3.1.8 Hospital Laboratory ...................................................................................................... 55 3.1.9 Physicians Office Lab (POLS) ....................................................................................... 55 3.1.10 Audit Body................................................................................................................. 56 3.1.11 Certification Body..................................................................................................... 56 3.2 Oncogenomics ................................................................................................................ 58 3.2.1 Carcinogenesis............................................................................................................. 58 3.2.2 Chromosomes, Genes and Epigenetics..................................................................... 60 3.2.2.1 Chromosomes....................................................................................................... 60 3.2.2.2 Genes .................................................................................................................... 62 3.2.2.3 Epigenetics............................................................................................................ 65 3.2.3 Cancer Genes .............................................................................................................. 66 3.2.4 Germline vs Somatic .................................................................................................... 68 3.2.5 Gene Panels, Single Gene Assays and Multiplexing ................................................. 69 3.2.6 Genomic Profiling ......................................................................................................... 70 HOWE SOUND RESEARCH Cancer Panel and Profiling Markets Page | 6 3.2.7 The Comprehensive Assay .......................................................................................... 71 3.2.8 Changing Clinical Role ................................................................................................ 71 3.2.9 The Cancer Screening Market Opportunity............................................................... 73 3.3 Cancer Management vs. Diagnosis ............................................................................... 74 3.3.1 The Role of Risk Assessment ......................................................................................... 74 3.3.2 Diagnosis ....................................................................................................................... 74 3.3.3 Managing ..................................................................................................................... 75 3.3.4 Monitoring ..................................................................................................................... 75 3.4 Phases of Adoption Looking into The Future ............................................................... 76 3.5 Structure of Industry Plays a Part ..................................................................................... 77 3.5.1 Hospital Testing Share .................................................................................................. 77 3.5.2 Economies of Scale...................................................................................................... 77 3.5.2.1 Hospital vs. Central Lab........................................................................................ 78 3.5.3 Physician Office Lab's.................................................................................................. 79 3.5.4 Physician's and POCT .................................................................................................. 80 3.6 Currently Available Large Comprehensive Assays........................................................ 80 3.7 Pricing Profiling vs. Whole Exome (or Genome) Sequencing ....................................... 83 3.7.1 Medicare Profile Pricing ............................................................................................... 83 3.7.2 Whole Exome Sequencing .......................................................................................... 83 4 Market Trends ...................................................................................................................85 4.1 Factors Driving Growth .................................................................................................... 86 4.1.1 Level of Care ................................................................................................................ 86 4.1.2 Companion Dx ............................................................................................................. 87 4.1.3 Immuno-oncology........................................................................................................ 87 HOWE SOUND RESEARCH Cancer Panel and Profiling Markets Page | 7 4.1.4 Liability........................................................................................................................... 87 4.1.5 The Aging Effect ........................................................................................................... 87 4.2 Factors Limiting Growth ................................................................................................... 90 4.2.1 State of knowledge...................................................................................................... 90 4.2.2 Genetic Blizzard ............................................................................................................ 91 4.2.3 Protocol Resistance...................................................................................................... 91 4.2.4 Regulation and coverage........................................................................................... 91 4.3 Instrumentation and Automation ................................................................................... 92 4.3.1 Instruments Key to Market Share................................................................................. 92 4.3.2 Bioinformatics Plays a Role .......................................................................................... 92 4.4 Diagnostic Technology Development ........................................................................... 93 4.4.1 Next Generation Sequencing Fuels a Revolution...................................................... 94 4.4.2 Single Cell Genomics Changes the Picture ............................................................... 95 4.4.3 Pharmacogenomics Blurs Diagnosis and Treatment................................................. 96 4.4.4 CGES Testing, A Brave New World .............................................................................. 96 4.4.5 Biochips/Giant magneto resistance based assay..................................................... 97 5 Cancer Panels & Profiles Recent Developments ..........................................................98 5.1 Recent Developments Importance and How to Use This Section ............................ 99 5.1.1 Importance of These Developments .......................................................................... 99 5.1.2 How to Use This Section................................................................................................ 99 5.2 Foundation Medicine, Fulgent Genetics to Launch Germline Testing ........................ 99 5.3 Advanced Genomics APAC, 3BIGS Partner on Cancer Testing ................................ 100 5.4 Lucence Assay Gets Coverage for Advanced Solid Tumors ..................................... 100 5.5 Foundation Medicine, AnHeart Therapeutics to Develop CDx for NSCLC Therapy. 101 HOWE SOUND RESEARCH Cancer Panel and Profiling Markets Page | 8 5.6 Roche CGP Assay Shows Concordance With Other NGS-Based Assays .................. 102 5.7 Precede Biosciences Emerges From Stealth With $57M ............................................. 104 5.8 Geneseeq Nabs CE Marks for Cancer Test Kits ........................................................... 105 5.9 Realm IDx Profiling Test Gets National Health Coverage in Japan............................ 106 5.10 Foundation Medicine, Merck KGaA to Collaborate on Companion Diagnostics ... 107 5.11 Guardant Health Secures Coverage for Liquid Biopsy Profiling Test.......................... 108 5.12 Myriad Genetics, Intermountain Precision Genomics Obtain NY Certification for Tumor Profiling............................................................................................................................. 109 5.13 Cota, Genomic Testing Coop Ink Oncology Partnership ........................................... 109 5.14 Euformatics, ViennaLab, Oncompass Win Liquid Biopsy Development Contract ... 110 5.15 Prenetics' Cancer Profiling Test Receives FDA Clearance.......................................... 111 5.16 Genetic Profiling May Identify Patients Who Do Not Need Radiation Therapy ........ 112 5.17 Thermo Fisher Introduces Homologous Score for Cancer Profiling ............................ 114 5.18 Genomic Test IDs Cancer Cells Early ............................................................................ 116 5.19 Caris Life Sciences to Offer Molecular Profiling Services............................................. 120 5.20 Geneseeq to Build Lab for Cancer Profiling in Brazil ................................................... 120 5.21 Genetron Health Adds New Assays to Pipeline ........................................................... 121 5.22 Illumina Obtains CE-IVD Marking for TSO Comprehensive Assay............................... 124 5.23 Guardant Health Receives Medicare Coverage for Guardant360 TissueNextTM Test 125 5.24 Cancer Screening Launch Approaches, Guardant Health Plans New Comprehensive Assay ............................................................................................................... 126 5.25 Thermo Fisher, Oncocyte Ink Deal for Cancer IVDs .................................................... 129 5.26 Local Cancer Genomic Profiling Options Grow, Though Central Labs Will Likely Keep Major Role ................................................................................................................................... 130 HOWE SOUND RESEARCH Cancer Panel and Profiling Markets Page | 9 5.27 Labcorp, CCORN Partner for Precision Oncology ...................................................... 138 5.28 Dante Labs Acquires Cambridge Cancer Genomics ................................................ 138 5.29 Celemics, Strand Partner on Integrated Platform for NGS Analysis ........................... 139 5.30 Myriad Genetics Recalibrates Breast Cancer Panel for All Ancestries ...................... 139 5.31 Burning Rock Revenues Rise.......................................................................................... 145 5.32 Caris Life Sciences to Expand Liquid Biopsy Testing .................................................... 147 5.33 OncoDiag Announces Multiplex Test for Bladder Cancer Recurrence..................... 151 5.34 Intermountain and Myriad Combine Test Offering ..................................................... 155 5.35 Illumina, Geneseeq to Offer Cancer Testing Kits in China.......................................... 159 5.36 Exact Sciences to Offer End-to-End Cancer Testing ................................................... 160 5.37 Guardant Health Turns to Tumor Tissue Sequencing ................................................... 163 5.38 Tempus Inks Oncology Testing Collaboration With Bayer........................................... 167 5.39 Biocartis Collaborating With GeneproDx, Endpoint Health on Tests for Idylla Platform 168 5.40 Wales to Routinely Screen Cancer Patients With Yourgene Elucigene Test ............. 169 5.41 Metastatic Cancer Markers Identified in Clinical WGS Study..................................... 170 5.42 Stitch Bio Bets on CRISPR Tech ...................................................................................... 173 5.43 Bayer, LifeLabs Launch Free NTRK Genetic Testing Program ..................................... 177 5.44 Foundation Medicine Liquid Biopsy Gets FDA Approval for Multiple Companion Dx 178 5.45 Progress, Challenges in Liquid Biopsy Reimbursement................................................ 179 5.46 Israeli Startup Curesponse Raises $6M .......................................................................... 183 5.47 Invitae, ArcherDX Merge to Advance Precision Oncology Offerings ....................... 184 5.48 MD Anderson Precision Oncology Decision Support to Use Philips' Informatics Solution 185 HOWE SOUND RESEARCH Cancer Panel and Profiling Markets Page | 10 5.49 NeoGenomics, Lilly Oncology Partner for Thyroid Cancer Testing Program............. 186 5.50 Germline Results Guides Precision Therapy in Advanced Cancer ............................ 186 5.51 FDA Clears Cancer Genomic Profiling Kit From Personal Genome Diagnostics ...... 191 5.52 ArcherDX, Premier Collaborate to Evaluate Genomic Sequencing Assay for Cancers 192 5.53 Labs Reporting Cancer Risk Mutations from Tumor Testing ........................................ 193 5.54 Users Begin Integrating Genomics Data for Clinical Decision Support...................... 201 5.55 Fujitsu Improves Efficiency in Cancer Genomic Medicine ......................................... 206 6 Profiles of Key Players .....................................................................................................209 6.1 10x Genomics, Inc.......................................................................................................... 210 6.2 Abbott Laboratories....................................................................................................... 212 6.3 AccuraGen Inc. ............................................................................................................. 214 6.4 Adaptive Biotechnologies ............................................................................................. 215 6.5 Admera Health, LLC....................................................................................................... 217 6.6 Aethlon Medical............................................................................................................. 218 6.7 Agilent ............................................................................................................................. 219 6.8 Amoy Diagnostics Co., Ltd. ........................................................................................... 221 6.9 Anchor Dx ....................................................................................................................... 222 6.10 ANGLE plc....................................................................................................................... 224 6.11 ARUP Laboratories.......................................................................................................... 225 6.12 AVIVA Systems Biology................................................................................................... 227 6.13 Baylor Miraca Genetics Laboratories ........................................................................... 228 6.14 Beckman Coulter Diagnostics (Danaher) .................................................................... 229 6.15 Becton, Dickinson and Company ................................................................................ 230 HOWE SOUND RESEARCH Cancer Panel and Profiling Markets Page | 11 6.16 BGI Genomics Co. Ltd ................................................................................................... 232 6.17 Bioarray Genetics........................................................................................................... 234 6.18 Biocartis ........................................................................................................................... 235 6.19 Biocept, Inc..................................................................................................................... 236 6.20 Biodesix Inc. .................................................................................................................... 237 6.21 BioFluidica ....................................................................................................................... 238 6.22 BioGenex ........................................................................................................................ 239 6.23 BioIVT ............................................................................................................................... 241 6.24 Biolidics Ltd...................................................................................................................... 242 6.25 bioMérieux Diagnostics.................................................................................................. 243 6.26 Bioneer Corporation ...................................................................................................... 246 6.27 Bio-Rad Laboratories, Inc............................................................................................... 248 6.28 Bio-Reference Laboratories........................................................................................... 249 6.29 Bio-Techne ...................................................................................................................... 250 6.30 Bioview ............................................................................................................................ 252 6.31 Bristol-Myers Squibb........................................................................................................ 253 6.32 Burning Rock ................................................................................................................... 255 6.33 C2i Genomics ................................................................................................................. 257 6.34 Cardiff Oncology ........................................................................................................... 258 6.35 Caris Molecular Diagnostics .......................................................................................... 259 6.36 Castle Biosciences, Inc. ................................................................................................. 260 6.37 Celemics ......................................................................................................................... 261 6.38 CellMax Life .................................................................................................................... 262 6.39 Cepheid (Danaher) ....................................................................................................... 263 HOWE SOUND RESEARCH Cancer Panel and Profiling Markets Page | 12 6.40 Charles River Laboratories ............................................................................................. 265 6.41 Circulogene.................................................................................................................... 266 6.42 Clearbridge Biomedics .................................................................................................. 267 6.43 Clinical Genomics .......................................................................................................... 268 6.44 Cytolumina Technologies Corp. ................................................................................... 269 6.45 Datar Cancer Genetics Limited.................................................................................... 270 6.46 Diagnologix LLC.............................................................................................................. 271 6.47 Diasorin S.p.A. ................................................................................................................. 272 6.48 Element Biosciences ...................................................................................................... 273 6.49 Enzo Biochem ................................................................................................................. 275 6.50 Epic Sciences.................................................................................................................. 276 6.51 Epigenomics AG............................................................................................................. 277 6.52 Eurofins Scientific ............................................................................................................ 278 6.53 Exact Sciences ............................................................................................................... 279 6.54 Fabric Genomics ............................................................................................................ 280 6.55 Fluxion Biosciences (Cell Microsystems) ....................................................................... 281 6.56 Freenome........................................................................................................................ 282 6.57 FUJIFILM Wako Diagnostics............................................................................................ 283 6.58 Fujirebio ........................................................................................................................... 284 6.59 GeneDx Holdings ........................................................................................................... 285 6.60 GeneFirst Ltd. .................................................................................................................. 286 6.61 Genetic Technologies Ltd. ............................................................................................ 287 6.62 Genetron Holdings ......................................................................................................... 288 6.63 GenomOncology........................................................................................................... 289 HOWE SOUND RESEARCH Cancer Panel and Profiling Markets Page | 13 6.64 GILUPI Nanomedizin....................................................................................................... 290 6.65 Guardant Health ............................................................................................................ 291 6.66 HansaBiomed ................................................................................................................. 292 6.67 HTG Molecular Diagnostics ........................................................................................... 293 6.68 iCellate............................................................................................................................ 294 6.69 ICON PLC ........................................................................................................................ 295 6.70 Illumina ............................................................................................................................ 296 6.71 Incell Dx........................................................................................................................... 297 6.72 Inivata ............................................................................................................................. 298 6.73 Invitae Corporation........................................................................................................ 299 6.74 Invivogen ........................................................................................................................ 300 6.75 Invivoscribe ..................................................................................................................... 301 6.76 J&J Innovative Medicine ............................................................................................... 302 6.77 KEW.................................................................................................................................. 303 6.78 Lucence Health.............................................................................................................. 304 6.79 Lunglife AI Inc ................................................................................................................. 305 6.80 MDNA Life SCIENCES, Inc............................................................................................... 306 6.81 MDx Health ..................................................................................................................... 307 6.82 Menarini Silicon Biosystems ............................................................................................ 308 6.83 Mesa Laboratories, Inc. ................................................................................................. 309 6.84 Millipore Sigma ............................................................................................................... 311 6.85 Miltenyi Biotec ................................................................................................................ 312 6.86 miR Scientific................................................................................................................... 313 6.87 Myriad Genetics ............................................................................................................. 315 HOWE SOUND RESEARCH Cancer Panel and Profiling Markets Page | 14 6.88 Nanostring....................................................................................................................... 317 6.89 NantHealth, Inc. ............................................................................................................. 319 6.90 Natera ............................................................................................................................. 321 6.91 NeoGenomics ................................................................................................................ 323 6.92 NGeneBio........................................................................................................................ 324 6.93 Novogene....................................................................................................................... 325 6.94 Oncimmune.................................................................................................................... 326 6.95 Oncocyte........................................................................................................................ 327 6.96 OncoDNA ....................................................................................................................... 328 6.97 OraLiva............................................................................................................................ 329 6.98 Oxford Nanopore Technologies ................................................................................... 330 6.99 Panagene....................................................................................................................... 332 6.100 Personalis..................................................................................................................... 333 6.101 Perthera....................................................................................................................... 334 6.102 PGDx (Labcorp).......................................................................................................... 335 6.103 Precipio ....................................................................................................................... 336 6.104 PrecisionMed .............................................................................................................. 337 6.105 Predictive Oncology .................................................................................................. 338 6.106 Prenetics...................................................................................................................... 340 6.107 Promega ..................................................................................................................... 341 6.108 Qiagen ........................................................................................................................ 343 6.109 QuidelOrtho ................................................................................................................ 345 6.110 Rarecells SAS............................................................................................................... 347 6.111 RareCyte ..................................................................................................................... 348 HOWE SOUND RESEARCH Cancer Panel and Profiling Markets Page | 15 6.112 Revvity ......................................................................................................................... 349 6.113 Roche Diagnostics ..................................................................................................... 351 6.114 Screencell ................................................................................................................... 353 6.115 Sherlock Biosciences .................................................................................................. 354 6.116 Siemens Healthineers ................................................................................................. 355 6.117 simfo GmbH ................................................................................................................ 356 6.118 Singlera Genomics Inc. .............................................................................................. 357 6.119 Singular Genomics ..................................................................................................... 358 6.120 Singulomics ................................................................................................................. 360 6.121 SkylineDx...................................................................................................................... 362 6.122 Standard BioTools ....................................................................................................... 363 6.123 Stilla Technologies ...................................................................................................... 365 6.124 Sysmex Inostics............................................................................................................ 366 6.125 Tempus Labs, Inc. ....................................................................................................... 367 6.126 Thermo Fisher Scientific .............................................................................................. 368 6.127 Todos Medical ............................................................................................................ 370 6.128 Ultima Genomics ........................................................................................................ 371 6.129 Variantyx ..................................................................................................................... 372 6.130 Vela Diagnostics......................................................................................................... 373 6.131 Veracyte ..................................................................................................................... 374 6.132 VolitionRX .................................................................................................................... 375 6.133 Vortex Biosciences ..................................................................................................... 376 7 The Global Market for Cancer Gene Panels and Profiles...........................................377 7.1 Global Market Overview by Country ........................................................................... 378 HOWE SOUND RESEARCH Cancer Panel and Profiling Markets Page | 16 7.1.1 Table Global Market by Country............................................................................ 378 7.1.2 Chart - Global Market by Country ............................................................................ 379 7.2 Global Market by Cancer Type - Overview................................................................. 380 7.2.1 Table Global Market by Cancer Type ................................................................... 380 7.2.2 Chart Global Market by Cancer Type Base/Final Year Comparison ............... 381 7.2.3 Chart Global Market by Cancer Type Base Year .............................................. 382 7.2.4 Chart Global Market by Cancer Type Final Year............................................... 383 7.2.5 Chart Global Market by Cancer Type Share by Year ....................................... 384 7.2.6 Chart Global Market by Cancer Type Segment Growth .................................. 385 7.3 Global Market by Application - Overview ................................................................... 386 7.3.1 Table Global Market by Application ..................................................................... 386 7.3.2 Chart Global Market by Application Base/Final Year Comparison ................. 387 7.3.3 Chart Global Market by Application Base Year ................................................ 388 7.3.4 Chart Global Market by Application Final Year................................................. 389 7.3.5 Chart Global Market by Application Share by Year.......................................... 390 7.3.6 Chart Global Market by Application Segment Growth .................................... 391 7.4 Global Market by Tissue - Overview ............................................................................. 392 7.4.1 Table Global Market by Tissue ................................................................................ 392 7.4.2 Chart Global Market by Tissue Base/Final Year Comparison ............................ 393 7.4.3 Chart Global Market by Tissue Base Year ........................................................... 394 7.4.4 Chart Global Market by Tissue Final Year ........................................................... 395 7.4.5 Chart Global Market by Tissue Share by Year .................................................... 396 7.4.6 Chart Global Market by Tissue Segment Growth............................................... 397 7.5 Global Market Germline & Somatic - Overview .......................................................... 398 HOWE SOUND RESEARCH Cancer Panel and Profiling Markets Page | 17 7.5.1 Table Global Market Germline & Somatic ............................................................ 398 7.5.2 Chart Global Market Germline & Somatic Base/Final Year Comparison ........ 399 7.5.3 Chart Global Market Germline & Somatic Base Year ....................................... 400 7.5.4 Chart Global Market Germline & Somatic Final Year........................................ 401 7.5.5 Chart Global Market Germline & Somatic Share by Year................................. 402 7.5.6 Chart Global Market Germline & Somatic Segment Growth ........................... 403 8 Global Cancer Gene Panels & Profiles Markets By Type of Cancer.......................404 8.1 Comprehensive Panels & Profiles.................................................................................. 405 8.1.1 Table Comprehensive Testing by Country............................................................. 405 8.1.2 Chart - Comprehensive Testing Growth ................................................................... 406 8.2 Breast Cancer Gene Testing ......................................................................................... 407 8.2.1 Table Breast Cancer Gene Testing by Country .................................................... 407 8.2.2 Chart - Breast Cancer Testing Growth...................................................................... 408 8.3 Colorectal Cancer Gene Testing ................................................................................. 409 8.3.1 Table Colorectal Cancer Gene Testing by Country............................................. 409 8.3.2 Chart - Colorectal Cancer Gene Testing Growth ................................................... 410 8.4 Gynecological Cancer Gene Testing .......................................................................... 411 8.4.1 Table Gynecological Cancer Gene Testing by Country ..................................... 411 8.4.2 Chart - Gynecological Cancer Gene Testing Growth............................................ 412 8.5 Blood Cancer Gene Testing .......................................................................................... 413 8.5.1 Table Blood Cancer Gene Testing by Country ..................................................... 413 8.5.2 Chart - Blood Cancer Gene Testing Growth ........................................................... 414 8.6 Prostate Cancer Gene Testing...................................................................................... 415 8.6.1 Table Prostate Cancer Gene Testing by Country ................................................. 415 HOWE SOUND RESEARCH Cancer Panel and Profiling Markets Page | 18 8.6.2 Chart - Prostate Cancer Testing Growth .................................................................. 416 8.7 Lung Cancer Gene Testing ........................................................................................... 417 8.7.1 Table Lung Cancer Gene Testing by Country....................................................... 417 8.7.2 Chart - Lung Cancer Gene Testing Growth ............................................................. 418 8.8 Other Cancer Gene Testing .......................................................................................... 419 8.8.1 Table Other Cancer Gene Testing by Country ..................................................... 419 8.8.2 Chart - Other Cancer Gene Testing Growth ........................................................... 420 9 Global Cancer Gene Panels & Profiles Markets By Type of Application ................421 9.1 Clinical Testing ................................................................................................................ 422 9.1.1 Table Clinical Testing by Country ........................................................................... 422 9.1.2 Chart - Clinical Testing Growth.................................................................................. 423 9.2 Pharmaceutical Testing ................................................................................................. 424 9.2.1 Table Pharmaceutical Testing by Country ............................................................ 424 9.2.2 Chart - Pharmaceutical Testing Growth................................................................... 425 9.3 Research Testing ............................................................................................................ 426 9.3.1 Table Research Testing by Country........................................................................ 426 9.3.2 Chart - Research Testing Growth .............................................................................. 427 10 Global Cancer Gene Panels & Profiles Markets By Tissue Type..........................428 10.1 Solid Tissue....................................................................................................................... 429 10.1.1 Table Solid Tissue Testing by Country.................................................................. 429 10.1.2 Chart Solid Tissue Testing Growth ....................................................................... 430 10.2 Liquid Tissue Testing ........................................................................................................ 431 10.2.1 Table Liquid Tissue Testing by Country ............................................................... 431 10.2.2 Chart - Liquid Tissue Testing Growth ...................................................................... 432 HOWE SOUND RESEARCH Cancer Panel and Profiling Markets Page | 19 11 Global Cancer Gene Testing Markets Germline and Somatic ..........................433 11.1 Global Market Somatic.................................................................................................. 434 11.1.1 Table Somatic by Country .................................................................................. 434 11.1.2 Chart - Somatic Testing Growth ............................................................................ 435 11.2 Global Market Germline ................................................................................................ 436 11.2.1 Table Germline by Country................................................................................. 436 11.2.2 Chart - Germline Testing Growth........................................................................... 437 12 Potential Market Opportunity Sizes..........................................................................438 12.1 Potential Cancer Screening by Country: Lung, Breast & Colorectal......................... 439 12.2 Potential Cancer Screening by Country: Prostate, Other Cancer & All Cancer...... 441 12.3 Potential Market Size - Cancer Diagnosis..................................................................... 443 12.4 Potential Market Size Therapy Selection.................................................................... 445 13 Appendices ...............................................................................................................447 13.1 Growth of Approved IVD Test Menu ............................................................................ 448 13.2 Growth of Approved Average IVD Test Fee ................................................................ 449 13.3 The Most Used IVD Assays.............................................................................................. 450 13.4 The Highest Grossing Assays .......................................................................................... 455 13.5 Laboratory Fees Schedule............................................................................................. 462 HOWE SOUND RESEARCH Cancer Panel and Profiling Markets Page | 20 Table of Tables Table 1 Market Players by Type ..................................................................................................... 52 Table 2 The Base Pairs...................................................................................................................... 63 Table 3 Current Assays .................................................................................................................... 80 Table 4 Relevant Pricing Table ....................................................................................................... 83 Table 5 Five Factors Driving Growth ............................................................................................... 86 Table 6 Four Factors Limiting Growth ............................................................................................. 90 Table 7 Key Diagnostic Laboratory Technology Trends ............................................................... 93 Table 8 Next Generation Sequencing Technologies Speed and Cost .................................... 94 Table 9 - Global Cancer Panel Market by Region...................................................................... 378 Table 10 Global Market by Cancer Type .................................................................................... 380 Table 11 Global Market by Application....................................................................................... 386 Table 12 Global Market by Tissue ................................................................................................. 392 Table 13 Global Market Germline & Somatic ............................................................................. 398 Table 14 Comprehensive Testing by Country.............................................................................. 405 Table 15 Breast Cancer Gene Testing by Country..................................................................... 407 Table 16 Colorectal Cancer Gene Testing by Country.............................................................. 409 Table 17 Gynecological Cancer Testing by Country ................................................................. 411 Table 18 Blood Cancer Gene Testing by Country ...................................................................... 413 Table 19 Prostate Cancer Gene Testing by Country .................................................................. 415 Table 20 Lung Cancer Gene Testing by Country........................................................................ 417 HOWE SOUND RESEARCH Cancer Panel and Profiling Markets Page | 21 Table 21 Other Cancer Gene Testing by Country ...................................................................... 419 Table 22 Clinical Testing by Country ............................................................................................ 422 Table 23 Pharmaceutical Testing by Country ............................................................................ 424 Table 24 Research Testing by Country......................................................................................... 426 Table 25 Solid Tissue Testing by Country....................................................................................... 429 Table 26 Liquid Tissue Testing by Country ................................................................................... 431 Table 27 Somatic by Country ...................................................................................................... 434 Table 28 Germline by Country...................................................................................................... 436 Table 29 Potential Screening Market: Lung, Breast & Colorectal .............................................. 439 Table 30 Potential Screening Market: Prostate, Other & All ....................................................... 441 Table 31 Potential Cancer Diagnosis Market Size ....................................................................... 443 Table 32 Potential Cancer Management Market Size ............................................................... 445 Table 33 The Most Common Assays ............................................................................................ 450 Table 34 Largest Revenue Assays................................................................................................. 456 Table 35 Clinical Lab Fee Schedule ............................................................................................. 462 HOWE SOUND RESEARCH Cancer Panel and Profiling Markets Page | 22 Table of Figures Figure 1 VistSeq Hereditary Cancer Panel..................................................................................... 38 Figure 2 Global Healthcare Spending ........................................................................................... 46 Figure 3 The Road to Diagnostics ................................................................................................... 50 Figure 4 The Genomic Progression of Cancer............................................................................... 59 Figure 5 DNA Strands and Chromosomes ..................................................................................... 60 Figure 6 Karyogram of Human Chromosomes .............................................................................. 61 Figure 7 Size of Various Genomes .................................................................................................. 64 Figure 8 Germline vs Somatic Mutations........................................................................................ 68 Figure 9 Comparing Genomic Diagnostic and Traditional Testing ............................................. 72 Figure 10 The Changing Age of The World's Population.............................................................. 88 Figure 11 Health Care Consumption by Age ................................................................................ 89 Figure 12 Cancer Incidence - Age at Diagnosis ........................................................................... 89 Figure 13 Base Year Country Global Share ................................................................................. 379 Figure 14 Global Market by Cancer - Base vs. Final Year .......................................................... 381 Figure 15 Cancer Panel Market Base Year.................................................................................. 382 Figure 16 Cancer Panel Market Final Year .................................................................................. 383 Figure 17 Cancer Type Share by Year ......................................................................................... 384 Figure 18 Cancer Type Segment Growth .................................................................................... 385 Figure 19 Global Market by Cancer - Base vs. Final Year .......................................................... 387 Figure 20 Cancer Panel Market Base Year.................................................................................. 388 Figure 21 Cancer Panel Market Final Year .................................................................................. 389 HOWE SOUND RESEARCH Cancer Panel and Profiling Markets Page | 23 Figure 22 Application Share by Year............................................................................................ 390 Figure 23 Application Segment Growth ...................................................................................... 391 Figure 24 Global Market by Cancer - Base vs. Final Year .......................................................... 393 Figure 25 Cancer Panel Market Base Year.................................................................................. 394 Figure 26 Cancer Panel Market Final Year .................................................................................. 395 Figure 27 Tissue Share by Year ...................................................................................................... 396 Figure 28 Tissue Segment Growth................................................................................................. 397 Figure 29 Germline & Somatic - Base vs. Final Year .................................................................... 399 Figure 30 Germline & Somatic Market Base Year ....................................................................... 400 Figure 31 Germline & Somatic Market Final Year........................................................................ 401 Figure 32 Germline & Somatic Share by Year ............................................................................. 402 Figure 33 Germline & Somatic Segment Growth ........................................................................ 403 Figure 34 Comprehensive Testing Growth................................................................................... 406 Figure 35 Breast Cancer Testing Growth...................................................................................... 408 Figure 36 Colorectal Cancer Gene Testing Growth ................................................................... 410 Figure 37 Gynecological Cancer Testing Growth ...................................................................... 412 Figure 38 Blood Cancer Gene Testing Growth ........................................................................... 414 Figure 39 Prostate Cancer Gene Testing Growth ....................................................................... 416 Figure 40 Lung Cancer Gene Testing Growth ............................................................................. 418 Figure 41 Other Cancer Gene Testing Growth ........................................................................... 420 Figure 42 Clinical Testing Growth ................................................................................................. 423 Figure 43 Pharmaceutical Testing Growth................................................................................... 425 Figure 44 Research Testing Growth .............................................................................................. 427 Figure 45 Solid Tissue Testing Growth............................................................................................ 430 HOWE SOUND RESEARCH Cancer Panel and Profiling Markets Page | 24 Figure 46 Liquid Tissue Testing Growth.......................................................................................... 432 Figure 47 Somatic Testing Growth ................................................................................................ 435 Figure 48 Germline Testing Growth .............................................................................................. 437 Figure 49 IVD Test Menu Growth .................................................................................................. 448 Figure 50 IVD Test Average Fees A Ten Year View ................................................................... 449 HOWE SOUND RESEARCHMicrosoft: Print To PDF